The intratumoral microbiota biomarkers for predicting survival and efficacy of immunotherapy in patients with ovarian serous cystadenocarcinoma
Open Access
- 5 July 2024
- journal article
- research article
- Published by Springer Nature in Journal of Ovarian Research
- Vol. 17 (1) , 140
Abstract
Background: Ovarian serous cystadenocarcinoma, accounting for about 90% of ovarian cancers, is frequently diagnosed at advanced stages, leading to suboptimal treatment outcomes. Given the malignant nature of the disease, effective biomarkers for accurate prediction and personalized treatment remain an urgent clinical need. Methods: In this study, we analyzed the microbial contents of 453 ovarian serous cystadenocarcinoma and 68 adjacent non-cancerous samples. A univariate Cox regression model was used to identify microorganisms significantly associated with survival and a prognostic risk score model constructed using LASSO Cox regression analysis. Patients were subsequently categorized into high-risk and low-risk groups based on their risk scores. Results: Survival analysis revealed that patients in the low-risk group had a higher overall survival rate. A nomogram was constructed for easy visualization of the prognostic model. Analysis of immune cell infiltration and immune checkpoint gene expression in both groups showed that both parameters were positively correlated with the risk level, indicating an increased immune response in higher risk groups. Conclusion: Our findings suggest that microbial profiles in ovarian serous cystadenocarcinoma may serve as viable clinical prognostic indicators. This study provides novel insights into the potential impact of intratumoral microbial communities on disease prognosis and opens avenues for future therapeutic interventions targeting these microorganisms.Keywords
Funding Information
- Beijing Natural Science Foundation (L232075)
- The National Natural Science Foundation of China (82304151, 32100647)
- the Fundamental Research Funds for the Central Universities (3332023033)
- National Clinical Research Center for Obstetrics and Gynecology (No. BYSYSZKF2023014)
- the Cancer Hospital of Chinese Academy of Medical Sciences-Shenzhen Hospital Cooperation Fund (CFA202202023)
- Key Clinical Project of Peking University Third Hospital (No. BYSYZD2023036)
This publication has 53 references indexed in Scilit:
- Intratumoral microbiota: roles in cancer initiation, development and therapeutic efficacySignal Transduction and Targeted Therapy, 2023
- Metagenomic analysis of the microbiome of the upper reproductive tract: combating ovarian cancer through predictive, preventive, and personalized medicineEPMA Journal, 2022
- Unexpected guests in the tumor microenvironment: microbiome in cancerProtein & Cell, 2020
- A SIRPα‐Fc fusion protein enhances the antitumor effect of oncolytic adenovirus against ovarian cancerMolecular Oncology, 2020
- Nomograms in oncology: more than meets the eyeThe Lancet Oncology, 2015
- Role of the Microbiota in Immunity and InflammationCell, 2014
- Integrated genomic analyses of ovarian carcinomaNature, 2011
- Human gut microbiome: the second genome of human bodyProtein & Cell, 2010
- Role of tumor-associated macrophages in tumor progression and invasionCancer and Metastasis Reviews, 2006
- Therapeutic targeting of the tumor microenvironmentCancer Cell, 2005